Amyloid

Lecanemab: a review

Lecanemab: drawbacks to consider

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Clinical robustness of CSF pTau/Aβ42 ratio for Alzheimer’s disease diagnosis

Bringing the pTau/Aβ42 biomarker into the clinic

Associations between predicted brain age and Alzheimer’s Disease biomarkers

The value of plasma p-tau181 as a screening and diagnostic tool for Alzheimer’s disease

Prognostic blood biomarkers in the pre-clinical stages of Alzheimer’s disease

Blood biomarkers in Alzheimer’s disease: appropriate use recommendations

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Biomarkers of apathy in Alzheimer’s disease

Aβ coarse-grained plaque described in early onset Alzheimer’s disease

The use of Alzheimer’s disease plasma biomarkers in the clinic: further research needed

Revising the amyloid hypothesis in Alzheimer’s disease: the probabilistic model

Reframing the way we think about Alzheimer’s disease

The potential of vaccination for neurodegenerative disease